Popular weight-loss drugs “probably have little or no effect” on a person’s risk of developing one of the 13 obesity-related ...

Tantalizing results from small trials and anecdotes raised hopes that drugs like Ozempic could help. Despite setbacks, researchers aren’t giving up yet.

What if the race to get thin was quietly putting health at risk? That question is becoming harder to ignore as glucagon‑like ...

The WHO issues its first official guidance on GLP-1 drugs for obesity treatment, as the disease affects over one billion ...

A new study finds a possible association between GLP-1 drugs like semaglutide and chronic cough, though the authors are ...

Adults prescribed a GLP-1 agent had a 12% higher risk for developing a new chronic cough -- one that persists for over 8 ...

Novo Nordisk’s stock tumbles after its oral GLP-1 drug didn’t show a statistically significant benefit over a placebo against ...

Just this week, the World Health Organization released new guidelines recommending GLP-1 therapies as a long-term treatment for adults with obesity.

Starting Jan. 1, 2026, Pennsylvania will limit GLP‑1 weight‑loss drugs under Medicaid — threatening access for thousands of ...

The weight loss medications can be part of a long-term treatment strategy for adults, according to new World Health ...